Abacavir + Dolutegravir + Lamivudine: Advanced HIV Treatment from India
Abacavir + Dolutegravir + Lamivudine is a fixed-dose combination (FDC) antiretroviral medicine widely used for the treatment of HIV-1 infection. This once-daily combination contains two nucleoside reverse transcriptase inhibitors (NRTIs) and one integrase strand transfer inhibitor (INSTI), providing potent viral suppression with a high barrier to resistance when taken as prescribed. WHO continues to recommend dolutegravir-based antiretroviral therapy as a preferred treatment approach in many settings.
Cordium Pharmaceuticals Pvt. Ltd. is committed to supplying high-quality pharmaceutical products to global healthcare markets with reliable manufacturing, quality assurance, and international export support.
Mechanism of Action of Abacavir + Dolutegravir + Lamivudine
1. Abacavir (ABC) – NRTI
Abacavir is converted inside cells into its active metabolite, which competes with natural nucleotides during viral DNA synthesis. This causes premature termination of viral DNA formation, preventing HIV replication.
2. Dolutegravir (DTG) – Integrase Strand Transfer Inhibitor
Dolutegravir blocks the HIV integrase enzyme, preventing viral DNA from integrating into the host cell genome. Without integration, HIV cannot establish productive infection in new cells.
3. Lamivudine (3TC) – NRTI
Lamivudine is phosphorylated intracellularly to an active form that inhibits HIV reverse transcriptase and terminates viral DNA chain elongation.
Combined Action
The three medicines attack HIV at different stages of its life cycle:
Blocks reverse transcription
Prevents viral DNA synthesis
Stops viral DNA integration into human cells
Reduces viral load effectively
Supports immune system recovery by increasing CD4 cell counts
This multi-target mechanism helps achieve durable viral suppression and lowers the likelihood of resistance when adherence is maintained.
Uses of Abacavir + Dolutegravir + Lamivudine
This combination is indicated for:
Treatment of HIV-1 infection in appropriate adult and pediatric patients according to approved labeling
First-line antiretroviral therapy in eligible patients
Long-term viral suppression
Improvement of immune function
Reduction in HIV disease progression
Lowering the risk of HIV-related complications
Treatment decisions should always be made by qualified healthcare professionals, including appropriate screening (such as HLA-B*5701 testing before abacavir use) and clinical monitoring.
Benefits
Once-daily fixed-dose combination
High antiviral efficacy
High genetic barrier to resistance due to dolutegravir
Improved patient adherence
WHO-supported dolutegravir-based treatment strategies
Suitable for large-scale HIV treatment programs where clinically appropriate
Global Export Markets
Cordium Pharmaceuticals Pvt. Ltd. exports quality pharmaceutical products to international markets, including:
🇰🇪 Kenya
🇳🇬 Nigeria
🇬🇭 Ghana
🇵🇭 Philippines
🇻🇳 Vietnam
🇦🇪 UAE
🇸🇦 Saudi Arabia
🇺🇿 Uzbekistan
🇰🇿 Kazakhstan
🇺🇸 USA
🇬🇧 UK
🇿🇦 South Africa
Our export solutions support hospitals, government tenders, importers, pharmaceutical distributors, NGOs, and institutional buyers while complying with applicable regulatory requirements.
Why Choose Cordium Pharmaceuticals Pvt. Ltd.?
Trusted pharmaceutical exporter from India
International-quality manufacturing standards
Reliable global supply chain
Competitive pricing
Timely deliveries
Export documentation support
Private labeling and contract manufacturing
Dedicated customer support
